Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR)

Bibliographic Details
Title:	Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR)
Authors:	Fornecker, L., Delwail, V., Thieblemont, C., Ghesquieres, H., Bouabdallah, K., Tilly, H., Le Calloch, R., Morschhauser, F., Costello, R., Slama, B., Gyan, E., Chauchet, A., Ngirabacu, M., Durot, E., Choquet, S., Capdupuy, C., Le Goff, M., Voillat, L., Snauwaert, S., Amorim, S.
Source:	Hematological oncology. 41:437-437
Availability:	http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185005286.0x000001&indx=1&recIds=ETOCvdc_100185005286.0x000001
Database:	British Library Document Supply Centre Inside Serials & Conference Proceedings